NasdaqGS - BOATS Real Time Price USD
Vertex Pharmaceuticals Incorporated (VRTX)
475.20 +6.78 (+1.45%)
At close: June 24 at 4:00:01 PM EDT
472.69 -2.51 (-0.53%)
Overnight: 2:31:55 AM EDT
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trade VRTX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for VRTX
Chart does not reflect overnight price.
- Previous Close
468.42 - Open
471.38 - Bid 478.08 x 100
- Ask 463.73 x 100
- Day's Range
469.92 - 480.86 - 52 Week Range
362.50 - 507.92 - Volume
1,502,222 - Avg. Volume
1,287,462 - Market Cap (intraday)
120.608B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
28.17 - EPS (TTM)
16.87 - Earnings Date (est.) Aug 3, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
548.69
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
VRTX
4.82%
S&P 500 (^GSPC)
7.49%
1-Year Return
VRTX
5.54%
S&P 500 (^GSPC)
20.78%
3-Year Return
VRTX
36.95%
S&P 500 (^GSPC)
69.22%
5-Year Return
VRTX
147.58%
S&P 500 (^GSPC)
72.47%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/24/2026
Market Cap
120.61B
Enterprise Value
115.35B
Trailing P/E
28.20
Forward P/E
25.00
PEG Ratio (5yr expected)
1.79
Price/Sales (ttm)
10.00
Price/Book (mrq)
6.23
Enterprise Value/Revenue
9.44
Enterprise Value/EBITDA
23.16
Financial Highlights
Profitability and Income Statement
Profit Margin
35.51%
Return on Assets (ttm)
12.14%
Return on Equity (ttm)
24.20%
Revenue (ttm)
12.22B
Net Income Avi to Common (ttm)
4.34B
Diluted EPS (ttm)
16.87
Balance Sheet and Cash Flow
Total Cash (mrq)
7.25B
Total Debt/Equity (mrq)
10.26%
Levered Free Cash Flow (ttm)
2.78B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MorePipeline offers near-term catalysts
Vertex Pharmaceuticals Inc. develops therapies to address CF and other diseases. The company was founded in 1989 in Cambridge, Massachusetts, and has 6,400 employees. It has research programs and facilities in the U.S., the U.K., and Canada. The shares are a component of the S&P 500.
RatingPrice TargetThe major indices have gone from mixed to modestly higher at midday on Tuesday.
The major indices have gone from mixed to modestly higher at midday on Tuesday. There's a tug of war, with uncertainty over Iran causing gloom while excitement over AI is creating optimism. Crude oil is at $92 per barrel. The yield on the 10-year note is at 4.45%. The VIX volatility index is at 16.
Vertex Earnings: Cystic Fibrosis Franchise Supports Advancement of Pipeline and Commercial Efforts
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
RatingPrice TargetVertex: Positive Phase 3 Data for Povetacicept Brings $4.9 Billion Alpine Deal Closer to Payoff
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
RatingPrice Target